Takeaway

• Monkeypox is an emerging global threat; first-use data suggest that brincidofovir has poor efficacy.

Why this matters

• Brincidofovir produces reductions in viral PCR cycle thresholds but offers no clinical benefit and is associated with liver function issues.
• Tecovirimat (2-week course) appears to allow humoral...